子宫内膜癌术前分子分型:通过活检与配对子宫切除标本的验证
回顾性分析116例子宫内膜癌或子宫癌肉瘤患者,采用ProMisE算法基于错配修复蛋白和p53免疫组化及POLE突变分析进行分子分型,并比较活检与子宫切除标本的一致性。活检与子宫切除标本的MMR状态一致率为97%,p53状态为96%,POLE突变为99%,总体分子分型一致率为91%。活检标本分子分型可有效分层复发风险(p < 0.001),POLE突变肿瘤预后最佳,p53异常肿瘤预后最差。
要点
- 活检与子宫切除标本分子分型总体一致率91%,MMR、p53、POLE一致率分别为97%、96%、99%。
- 活检标本分子分型可有效分层复发风险(p < 0.001),POLE突变预后最佳,p53异常最差。
- 靶向57基因NGS panel在活检与子宫切除标本间共享64%的致癌突变。
核心结论
- 使用子宫内膜活检标本进行分子分型和靶向panel测序是可行的,与子宫切除标本结果高度一致。
- 该方法可实现术前风险评估,支持子宫内膜癌的个体化治疗规划。
研究设计与样本
- 回顾性分析2014年至2024年间治疗的116例子宫内膜癌或子宫癌肉瘤患者。
- 采用ProMisE算法基于错配修复蛋白和p53免疫组化及POLE突变分析进行分子分型。
- 对活检和子宫切除标本均进行靶向下一代测序(NGS),使用定制57基因panel评估基因突变一致性。
主要发现
- 活检与子宫切除标本一致率:MMR状态97%,p53状态96%,POLE突变99%,总体分子分型一致率91%。
- NGS共识别1943个基因突变,其中714个(37%)为致癌性,64%的致癌突变在两种标本类型间共享。
- 活检标本分子分型可有效分层复发风险(p < 0.001),POLE突变肿瘤预后最佳,p53异常肿瘤预后最差。
关键数值与推荐
- MMR状态一致率97%,p53状态一致率96%,POLE突变一致率99%,总体分子分型一致率91%。
- NGS识别1943个基因突变,714个(37%)为致癌性,64%在活检与子宫切除标本间共享。
- 活检标本分子分型对复发风险分层有统计学意义(p < 0.001)。
临床怎么用
- 作者认为,使用子宫内膜活检标本进行分子亚型和靶向panel测序可行,与子宫切除标本结果高度一致。
- 作者指出,该方法可实现术前风险评估,支持子宫内膜癌的个体化治疗规划。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the concordance of molecular classification between preoperative endometrial biopsy and corresponding hysterectomy specimens in endometrial cancer, and to assess the feasibility of using biopsy specimens for genomic profiling and recurrence risk stratification. METHODS: We retrospectively analyzed 116 patients with endometrial carcinoma or uterine carcinosarcoma treated between 2014 and 2024. Molecular classification was performed using the ProMisE algorithm based on immunohistochemistry (IHC) for mismatch repair (MMR) proteins and p53, along with POLE mutational analysis. In addition, targeted next-generation sequencing (NGS) with a custom 57-gene panel was performed on both biopsy and hysterectomy specimens to evaluate the concordance of gene mutations. RESULTS: The concordance rates between biopsy and hysterectomy specimens were 97 % for MMR status, 96 % for p53 status, and 99 % for POLE mutations, with an overall molecular classification concordance of 91 %. NGS identified 1943 gene mutations, of which 714 (37 %) were classified as oncogenic. Among these, 64 % were shared between the two specimen types. Molecular classification using biopsy specimens effectively stratified recurrence risk (p < 0.001), with POLE-mutated tumors showing the most favorable outcomes and p53-abnormal tumors the poorest. CONCLUSIONS: Molecular subtyping and targeted panel sequencing using endometrial biopsy specimens are feasible and show high concordance with hysterectomy-based results. This approach allows for preoperative risk assessment and supports personalized treatment planning in endometrial cancer.
引用
- Nozaki T, Sakamoto I, Kagami K, et al. Preoperative molecular classification of endometrial cancer: Validation through biopsy and matched hysterectomy specimens. Gynecol Oncol. 2025. PMID: 41175447. doi:10.1016/j.ygyno.2025.10.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。